Investigations in the last 10 years have revealed a new category of neurological diseases
mediated by antibodies against cell surface and synaptic proteins. There are currently 16 …

Recent medical advances have improved the understanding, diagnosis, and treatment of
paraneoplastic syndromes. These disorders arise from tumor secretion of hormones …

Background: Paraneoplastic neurological syndromes (PNS) are defined by the presence of
cancer and exclusion of other known causes of the neurological symptoms, but this criterion …

Background: Paraneoplastic neurological syndromes (PNS) almost invariably predate
detection of the malignancy. Screening for tumours is important in PNS as the tumour …

Major advances in the management of paraneoplastic neurologic disorders (PND) include
the detection of new antineuronal antibodies, the improved characterisation of known …

Lambert–Eaton myasthenic syndrome (LEMS) is a neuromuscular autoimmune disease that
has served as a model for autoimmunity and tumour immunology. In LEMS, the …

Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote
cancer and are characterised by an autoantibody response against antigens expressed by …

The concept of antibody mediated CNS disorders is relatively recent. The classical CNS
paraneoplastic neurological syndromes are thought to be T cell mediated, and the …

We review the neuronal antibodies described in CNS disorders in order to clarify their
diagnostic value, emphasize potentials pitfalls and limitations in the diagnosis of …

Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer
that are not caused by the tumor and its metastasis, or by infection, ischemia or metabolic …